Impact of FDA-Approved Drugs on the Prostaglandin Transporter OATP2A1/SLCO2A1
- 1 September 2017
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 106 (9) , 2483-2490
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science
- Smoking Research Foundation
This publication has 38 references indexed in Scilit:
- OATP2A1/SLCO2A1-mediated prostaglandin E2 loading into intracellular acidic compartments of macrophages contributes to exocytotic secretionBiochemical Pharmacology, 2015
- A Hereditary Enteropathy Caused by Mutations in the SLCO2A1 Gene, Encoding a Prostaglandin TransporterPLOS Genetics, 2015
- Inhibition of the Prostaglandin Transporter PGT Lowers Blood Pressure in Hypertensive Rats and MicePLOS ONE, 2015
- Prostaglandin Transporter (PGT/SLCO2A1) Protects the Lung from Bleomycin-Induced FibrosisPLOS ONE, 2015
- Prostaglandin Transporter Modulates Wound Healing in Diabetes by Regulating Prostaglandin-Induced AngiogenesisThe American Journal of Pathology, 2012
- Mutations in the prostaglandin transporter encoding geneSLCO2A1Cause primary hypertrophic osteoarthropathy and isolated digital clubbingHuman Mutation, 2012
- Failure of Postnatal Ductus Arteriosus Closure in Prostaglandin Transporter–Deficient MiceCirculation, 2010
- Identification of a New Class of Prostaglandin Transporter Inhibitors and Characterization of Their Biological Effects on Prostaglandin E2 TransportThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Prostaglandin Signaling in the Renal Collecting DuctJournal of Biological Chemistry, 2005
- Identification and Characterization of a Prostaglandin TransporterScience, 1995